Rheumatoid Arthritis

Rheumatoid Arthritis

Rheumatoid arthritis is a systemic autoimmune disease.

For reasons thought to be genetic, hormonal or environmental, immune system begins mistakenly attacking the joints of the body, most commonly both joints of the hands, feet, wrists, elbows, knees and ankles. This causes inflammation that leads to thickening of the synovium (tissue lining the joints) as well as swelling and pain.

Over time, the cartilage becomes damaged, loose and unstable resulting in reduced mobility and deformity. In some cases, it can also affect the cardiovascular or respiratory systems.

How Our Products Can Treat Rheumatoid Arthritis

We use products derived from human baby umbilical cords in all our therapy programs - Wharton's Jelly MSCs (wjMSCs). Our products are special because they can:

  • migrate to sites of injury (chemotaxis) [1,2].
  • communicate with and alter nearby cells (paracrine effect) [3,4,5].
  • encourage existing cells to self-repair (autocrine effect) [5,6,7].
  • prevent rejection by regulating the immune system (immunomodulation) [1,2,8,9,10,11,12,13,14,15].
  • reduce inflammation [2,13,14,15,16,17,18,19,20,21,22].
  • prevent cells from dying (apoptosis) [1,2,3,15,20,23,24,25].
  • transform into bone (osteogenic) and cartilage (chondrogenic) [26,27].
  • incapable of forming tumours [1,10,11,28,29].
  • encourage existing cells to adapt (plasticity) [30,31,32].


Treating Rheumatoid Arthritis

There are currently three clinical trials exploring the use of wjMSCs in the treatment of rheumatoid arthritis. These have been registered but results and findings have yet to be posted [33,34,35].

A study performed by a Chinese study in 2013 divided 172 patients into two groups. One group received only disease-modifying anti-rheumatic drugs (DMARDs) while the other group received both DMARDs and intravenous infusions of wjMSCs. The study found that patients in the DMARDs + wjMSCs group experienced significant remission of disease according to the American College of Rheumatology improvement criteria, the 28-joint disease activity score, and the Health Assessment Questionnaire. It further found that the therapeutic effects maintained for three to six months without follow-up infusions and correlated with an increased percentage of regulatory T cells in peripheral blood [36].

The following year, physicians from the Department of Rheumatology and Immunology of Nanjing University Medical School treated a 42-year-old woman who had a 28-year history of rheumatoid arthritis, hypertension and type 2 diabetes mellitus. The patient had developed an infection of her central nervous system and recurrent ulcers on her right leg that did not respond to conventional therapy methods. wjMSCs were administered six months later. One month after the first transplantation, new connective tissue and microscopic blood vessels were observed at the ulcer sites. The patient was given two more doses of wjMSCs one and a half and three months later, respectively. Three months after her first transplantation, physicians noted that her ulcers had significantly healed with the help of daily medication for maintenance [37]

In 2018, Chinese research scientist treated rats that had collagen-induced arthritis (CIA) with wjMSCs. During the study, 40 rats were randomly divided into four groups and their blood samples were collected at different time points to measure levels of serum cartilage oligomeric matrix protein (COMP) – a protein primarily present in cartilage and a marker of cartilage turnover [38]. The study found a total success rate of 83% with an improvement of joint symptoms most evident when wjMSC transplantation was combined with methotrexate. The therapy protocol was able to successfully relieve symptoms of arthritis by down-regulating the expression and serum levels of COMP in the synovial membrane CIA rats [39]


Cyrona’s Program

Achieving high standards in our work is of paramount importance to us. Depending on a patient’s needs, we combine our premium grade Passage 2 wjMSCs with physiotherapy, occupational therapy, speech and language therapy and/or rehabilitative medicine. 

Learn more about our Products and Programs.


Why Choose Cyrona?

  • Latest cellular research and technology.
  • Unique, tailored therapy outlines.
  • Products that meet international standards.
  • Microbiology & clinical team with extensive experience in advanced medicine.
  • Board-certified physicians geared toward patient safety.
  • Fact-based information from clinical studies and trials.
  • No outlandish promises of a one-stop-cure or false improvement rates.


Therapy Packages

All our therapy packages come inclusive of:



  • Premium grade Passage 2 wjMSCs.
  • Treatment by qualified specialist(s).
  • Certificate of Analysis (CoA).
  • Airport transfer.
  • Transportation to & from therapy session(s).
  • Accommodation.
  • Hospital room for therapy.



  • Premium grade Passage 2 wjMSCs.
  • Treatment by qualified specialist(s).
  • Certificate of Analysis (CoA).
  • Transportation to & from therapy session(s).
  • Hospital room for therapy.


How Do We Proceed

All our therapies are charged based on the number of wjMSCs and supplementary infusions required for the patient’s specific condition. As no two people are alike, our specialists review each patient’s medical reports before tailoring a therapy catered to addressing his or her individual needs.

You may chat with one of our Customer Care Representatives or send an e-mail detailing the patient’s condition to one of our Liaison Officers. It would expedite the process if you can provide us with:

  • Imaging results (MRI scan / CT scan / X-Ray).
  • Haematology reports (blood test).
  • Doctor’s assessment reports.
  • Pictures or videos of the patient (if relevant).

Upon getting in touch with us, a Liaison Officer evaluates and assigns the case to the specialist best equipped to treat the condition. A therapy, unique only to the patient, is drawn up and a price quoted accordingly.

Should you decide to proceed with therapy, our specialists require that all patients have Cancer Marker Screening performed in their country of residence before travelling to us for therapy. If the patient has had Cancer Marker Screening within the last 3 months, you may e-mail those results to us. In the event that the patient’s Cancer Marker Screening results are not satisfactory, our specialists will refuse to proceed with therapy. It is for this reason that we request that patients have Cancer Marker Screening performed in their country of residence prior to travelling to us.

One week prior to arrival, a deposit payment is required in order to arrange accommodation and transportation.

Full payment is required to be made one-day prior to therapy commencement.

Post-treatment, our specialist will provide the patient with a post-treatment protocol as well as what to expect on his or her journey towards a better, and hopefully, healthier new life.


Kindly get in touch with us for the sources listed throughout this article.


More than 1000 people are choosing Cyrona Health


Our Facilities

Download a complimentary eBook about

Download our eBook and receive our weekly in-depth and exclusive newsletter about .

Rheumatoid Arthritis eBook